Adrenergic modifiers - Biotech, Pharma and Life Science Channel

19:47 EDT 29th March 2015 | BioPortfolio

PubMed Articles [389 Associated PubMed Articles listed on BioPortfolio]

Polymorphisms in Oxytocin and α1a Adrenergic Receptor Genes and Their Effects on Production Traits in Dairy Buffaloes.

The use of molecular markers may auxiliary the buffalo breeding. The oxytocin (OXT) and the adrenergic receptor α1A (ADRA1A) may be involved in milk ejection in ruminants. The aim of this study was t...

Activation of Classical Brown Adipocytes in the Adult Human Perirenal Depot Is Highly Correlated with PRDM16-EHMT1 Complex Expression.

Brown fat generates heat to protect against cold and obesity. Adrenergic stimulation activates the thermogenic program of brown adipocytes. Although the bioactivity of brown adipose tissue in adult hu...

Tandem differential mobility spectrometry with ion dissociation in air at ambient pressure and temperature.

Proton-bound dimers were dissociated to protonated monomers in air at ambient pressure and temperature using electric fields of ultrahigh Field Asymmetric Ion Mobility Spectrometry (ultraFAIMS) with t...

α1B-Adrenergic Receptors Differentially Associate with Rab Proteins during Homologous and Heterologous Desensitization.

Internalization of G protein-coupled receptors can be triggered by agonists or by other stimuli. The process begins within seconds of cell activation and contributes to receptor desensitization. The R...

Sulfate-based anionic diblock copolymer nanoparticles for efficient occlusion within zinc oxide.

Occlusion of copolymer particles within inorganic crystalline hosts not only provides a model for understanding the crystallisation process, but also may offer a direct route for the preparation of no...

Shared Dosimetry Error in Epidemiological Dose-Response Analyses.

Radiation dose reconstruction systems for large-scale epidemiological studies are sophisticated both in providing estimates of dose and in representing dosimetry uncertainty. For example, a computer p...

ASM-024, a Piperazinium Compound, Promotes the In Vitro Relaxation of β2-Adrenoreceptor Desensitized Tracheas.

Inhaled β2-adrenoreceptor agonists are widely used in asthma and chronic obstructive pulmonary disease (COPD) for bronchoconstriction relief. β2-adrenoreceptor agonists relax airway smooth muscle ce...

Hierarchical Mesoporous In2O3 with Enhanced CO Sensing and Photocatalytic Performance: Distinct Morphologies of In(OH)3 via Self Assembly Coupled in-situ Solid-Solid Transformation.

The present investigation details our interesting findings and insights into the evolution of exotic hierarchical superstructures of In(OH)3 under solvothermal conditions. Controlled variation of reac...

β2-AR signaling controls trastuzumab resistance-dependent pathway.

Currently, trastuzumab resistance is a major clinical problem in the treatment of Her2-overexpressing breast cancer. The underlying molecular mechanisms are not fully understood. Our previous study de...

Characterization of the Binding Properties of Molecularly Imprinted Polymers.

: The defining characteristic of the binding sites of any particular molecularly imprinted material is heterogeneity: that is, they are not all identical. Nonetheless, it is useful to study their fund...

News Articles [43 Associated News Articles listed on BioPortfolio]

FDA panel backs Breo Ellipta for adults, not children

FDA's Pulmonary-Allergy Drugs Advisory and Drug Safety and Risk Management Advisory committees voted 16-4 to recommend approval of Breo Ellipta fluticasone furoate/vilanterol from GlaxoSmithKline plc ...

AstraZeneca meets in Phase III COPD trials

AstraZeneca plc (LSE:AZN; NYSE:AZN) said PT003 met the primary endpoint of the Phase III PINNACLE 1 and PINNACLE 2 studies to treat chronic obstructive pulminary disease (COPD). In both trials, PT003 ...

Adolescents FDA's greatest concern for GSK's Breo in asthma

Breo, a combination of fluticasone furoate (FF), an inhaled corticosteroid (ICS), and vilanterol (VI), a long-acting beta2 adrenergic agonist (LABA), already is approved in the US as a long-term, once...

FDA reviewers focus on safety of Breo Ellipta

FDA will ask its Pulmonary-Allergy Drugs and Drug Safety and Risk Management advisory committees to vote on whether to recommend a large pre- or post-approval safety trial to evaluate serious asthma o...

Administration of Biologic Infusions: A Position Statement of the Rheumatology Nurses Society

The Rheumatology Nurses Society (RNS) is dedicated to the public’s expectation of excellence in care and safe practice for patients with rheumatic diseases. Greenville, SC (PRWEB) March 03, 2015 Th...

Neuronal ensembles sufficient for recovery sleep and the sedative actions of α2 adrenergic agonists

The authors use TetTag pharmacogenetics to mark neuronal ensembles activated in the preoptic hypothalamus during dexmedeotomidine-induced sedation or recovery sleep. When these ensembles were selectiv...

Sosei to acquire Heptares for up to $400M

Sosei Group Corp. (Tokyo:4565) will acquire Heptares Therapeutics Ltd. (Welwyn Garden City, U.K.) for $180 million up front and up to $220 million in milestones.Sosei will receive Heptares' StaR drug ...

IMCD to Expand Plastic Additives Partnership with Dow into GSA and the UK

IMCD is expanding its partnership with Dow Europe GmbH for Paraloid impact modifiers and Surecel processing aids into the GSA region (Germany, Switzerland and Austria) and the UK.

GSK expects Advair price crunch, ViiV IPO decision

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) expects continued price pressure on respiratory drug Advair salmeterol/fluticasone propionate this year and said it is likely to reveal a decision on a partial ...

Rett Syndrome Research Trust Awards $5.8 Million to Advance the Development of Treatments and Cures for Rett Syndrome and MECP2 Disorders

Today the Rett Syndrome Research Trust (RSRT) announced research investments of $5.8 million awarded in 2014. RSRT’s sole and urgent goal is to abolish Rett Syndrome and related disorders. Trumbull,...

Events [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

Innate Immunotherapeutics Limited

Innate Immunotherapeutics Limited is a public unlisted biopharmaceutical company based in Auckland, New Zealand. The company is focused on the development of a new generation of i...

Innate Therapeutics Limited

Innate Therapeutics Limited is a public unlisted biopharmaceutical company based in Auckland. The company is focused on the development of a new generation of immune response modi...

Clinical Trials [85 Associated Clinical Trials listed on BioPortfolio]

Use of an Oral Beta-2 Agonist in Persons With Spinal Cord Injury

The primary purpose of this study is to determine the effect of administration of the oral beta-2 adrenergic agonist, albuterol, on respiratory muscle strength in individuals with cervical...

Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure

This study is being done to compare the effects of bucindolol hydrochloride (bucindolol) to metoprolol succinate (Toprol-XL) on the recurrence of symptomatic atrial fibrillation/atrial flu...

Darbepoetin Alfa in Anemic Low or Intermediate-1 Risk MDS Subjects

This is a Phase 3, multicenter, randomised, double-blind, placebo-controlled trial of darbepoetin alfa 500 μg administered once every 3 weeks (Q3W) to approximately 141 low or intermediat...

TAKO-TSUBO Cardiomyopathy and Genetic

This is a case-control association study with multicentric prospective recruitment. Tako-TSUBO cardiomyopathy is a new clinical entity mimicking an acute coronary syndrome. It is characte...

Molecular Immunohematology in Ethiopian Sub-Populations

Alloimmunization to blood products in transfused patients is a recognized management challenge in the clinical setting. In particular the ethnic and racial specificity of RBC antigens and ...

Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia

Cannabis use disorders are an important public health problem in the United States, but no effective pharmacotherapies are available to treat these disorders. People with schizophrenia ar...

Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome

From 1999, several studies have showed that the use of vasoconstrictors in association with albumin are effective in the treatment of hepatorenal syndrome (HRS). The rationale of the use o...

Stress During Deep Sedation With Propofol With and Without Alfentanil

This is a randomized clinical trial of deep procedural sedation with propofol with and without supplemental alfentanil. Patients will be assessed for total and fractionated serum catechol...

Study to Evaluate Esmolol (Brevibloc) to Manage Cardiac Function in Patients With Subarachnoid Hemorrhage

The purpose of this study is to evaluate the clinical effect of esmolol treatment on cardiac function and electrophysiology; to assess the effects of esmolol treatment on serum adrenergic ...

Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM)

To compare two standard treatment strategies for atrial fibrillation: ventricular rate control and anticoagulation vs. rhythm control and anticoagulation.

Medical and Biotech [MESH] Definitions

Drugs that act on adrenergic receptors or affect the life cycle of adrenergic transmitters. Included here are adrenergic agonists and antagonists and agents that affect the synthesis, storage, uptake, metabolism, or release of adrenergic transmitters.

Drugs that bind to but do not activate ADRENERGIC RECEPTORS. Adrenergic antagonists block the actions of the endogenous adrenergic transmitters EPINEPHRINE and NOREPINEPHRINE.

A subclass of beta-adrenergic receptors (RECEPTORS, ADRENERGIC, BETA). beta-3 Adrenergic receptors are the predominant beta-adrenergic receptor type expressed in white and brown ADIPOCYTES and are involved in modulating ENERGY METABOLISM and THERMOGENESIS.

Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.

Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety.

Search BioPortfolio:
Loading
Advertisement
Advertisement
review and buy Adrenergic modifiers market research data and corporate reports here

Channels Quicklinks